Working… Menu

Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03004001
Recruitment Status : Unknown
Verified March 2017 by Gloria Vega, Dallas VA Medical Center.
Recruitment status was:  Recruiting
First Posted : December 28, 2016
Last Update Posted : March 13, 2017
Regeneron Pharmaceuticals
Aventis Pharmaceuticals
Information provided by (Responsible Party):
Gloria Vega, Dallas VA Medical Center